• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对 NY-ESO-1 的新型 TCR 推动肉瘤研究进展。

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1.

机构信息

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology, Chicago, IL, USA.

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology, Chicago, IL, USA.

出版信息

Cell Rep Med. 2023 Aug 15;4(8):101159. doi: 10.1016/j.xcrm.2023.101159.

DOI:10.1016/j.xcrm.2023.101159
PMID:37586326
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10439265/
Abstract

A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al. is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.

摘要

潘等人开展的一项 I 期临床试验证明了新型 NY-ESO-1 特异性 TCR-T 细胞的安全性和有效性，这是过继性 T 细胞疗法在晚期软组织肉瘤临床实践中的重大进展。

相似文献

1
Pushing forward in sarcoma with a new TCR targeting NY-ESO-1.针对 NY-ESO-1 的新型 TCR 推动肉瘤研究进展。
Cell Rep Med. 2023 Aug 15;4(8):101159. doi: 10.1016/j.xcrm.2023.101159.
2
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.一项关于NY-ESO-1特异性T细胞受体工程化T细胞疗法联合淋巴结靶向纳米颗粒肽疫苗治疗晚期软组织肉瘤的1期试验。
Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17.
3
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.评估 NY-ESO-1 特异性 TCR T 细胞在 HLA-A∗02:01 晚期软组织肉瘤患者中的安全性和疗效的 1 期临床试验。
Cell Rep Med. 2023 Aug 15;4(8):101133. doi: 10.1016/j.xcrm.2023.101133.
4
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.采用 NY-ESO-1 SPEAR T 细胞过继转移后滑膜肉瘤的全身和局部免疫。
J Immunother Cancer. 2019 Oct 24;7(1):276. doi: 10.1186/s40425-019-0762-2.
5
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.一项使用经NY-ESO-1反应性T细胞受体基因工程改造的淋巴细胞的试点试验：长期随访及与反应的相关性。
Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.
6
A rare population of tumor antigen-specific CD4CD8 double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.一种罕见的肿瘤抗原特异性 CD4CD8 双阳性 αβ T 淋巴细胞群体，为工程化治疗性 T 细胞提供了独特的 CD8 非依赖性 TCR 基因。
J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.
7
NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.滑膜肉瘤及其他间叶性肿瘤中 NY-ESO-1 的表达：基于 NY-ESO-1 的靶向治疗和鉴别诊断的意义。
Mod Pathol. 2012 Jun;25(6):854-8. doi: 10.1038/modpathol.2012.31. Epub 2012 Mar 2.
8
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 T Cells in Synovial Sarcoma.过继转移 NY-ESO-1 细胞在滑膜肉瘤中与抗肿瘤活性相关联，且具有持久的存在。
Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.
9
Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.来自抗原阴性宿主的有效的 NY-ESO-1 特异性 MHC II 限制性 T 细胞受体可增强肿瘤消退。
J Clin Invest. 2019 Jan 2;129(1):324-335. doi: 10.1172/JCI120391. Epub 2018 Dec 10.
10
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.CMB305 联合阿替利珠单抗对比阿替利珠单抗单药治疗表达 NY-ESO-1 的软组织肉瘤的 II 期随机研究
J Clin Oncol. 2022 Apr 20;40(12):1291-1300. doi: 10.1200/JCO.20.03452. Epub 2021 Jul 14.

引用本文的文献

1
Analysis of prostatic spindle cell lesions: Three case reports and literature review.前列腺梭形细胞病变分析：三例报告及文献综述
Medicine (Baltimore). 2025 Aug 15;104(33):e43768. doi: 10.1097/MD.0000000000043768.
2
Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy.晚期滑膜肉瘤的治疗策略：从化疗到T细胞受体工程化T细胞疗法
Int J Clin Oncol. 2025 May;30(5):878-885. doi: 10.1007/s10147-025-02744-y. Epub 2025 Mar 24.
3
Recent clinical researches and technological development in TIL therapy.TIL 疗法的最新临床研究和技术进展。
Cancer Immunol Immunother. 2024 Sep 12;73(11):232. doi: 10.1007/s00262-024-03793-4.

本文引用的文献

1
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.评估 NY-ESO-1 特异性 TCR T 细胞在 HLA-A∗02:01 晚期软组织肉瘤患者中的安全性和疗效的 1 期临床试验。
Cell Rep Med. 2023 Aug 15;4(8):101133. doi: 10.1016/j.xcrm.2023.101133.
2
Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial.自体 T 细胞疗法治疗 HLA-A*02 患者的 MAGE-A4 实体瘤：一项 1 期临床试验。
Nat Med. 2023 Jan;29(1):104-114. doi: 10.1038/s41591-022-02128-z. Epub 2023 Jan 9.
3
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 T Cells in Synovial Sarcoma.过继转移 NY-ESO-1 细胞在滑膜肉瘤中与抗肿瘤活性相关联，且具有持久的存在。
Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.
4
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.四聚体导向、细胞分选辅助生产临床级自体 NY-ESO-1 特异性 CD8(+) T 细胞。
J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.
5
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.NY-ESO-1 是黏液样/圆细胞脂肪肉瘤患者普遍存在的免疫治疗靶抗原。
Cancer. 2012 Sep 15;118(18):4564-70. doi: 10.1002/cncr.27446. Epub 2012 Feb 22.
6
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.采用针对 NY-ESO-1 的基因工程化淋巴细胞治疗转移性滑膜细胞肉瘤和黑色素瘤患者的肿瘤消退。
J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.
7
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.癌胚抗原：癌症免疫治疗中不断扩大的靶点家族。
Immunol Rev. 2002 Oct;188:22-32. doi: 10.1034/j.1600-065x.2002.18803.x.
8
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.单相和双相滑膜肉瘤大量表达癌/睾丸抗原NY-ESO-1，但不表达MAGE-A1或CT7。
Int J Cancer. 2001 Oct 15;94(2):252-6. doi: 10.1002/ijc.1451.
9
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.一种通过自体抗体筛选在人类癌症中异常表达的睾丸抗原。
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8. doi: 10.1073/pnas.94.5.1914.